The risks and benefits of antidepressant treatment for youth depression

被引：37

作者：

Bridge, JA ^{[1
]}

Salary, CB ^{[1
]}

Birmaher, B ^{[1
]}

Asare, AG ^{[1
]}

Brent, DA ^{[1
]}

机构：

[1] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA

来源：

ANNALS OF MEDICINE | 2005年 / 37卷 / 06期

关键词：

antidepressants; adolescents; children; depression; suicidality;

D O I：

10.1080/07853890500284937

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The U.S. Food and Drug Administration (FDA) has mandated that all antidepressants carry a 'black box' warning label indicating that antidepressants increase the risk of suicidality in youth taking these medications. In the U.K., the Medicine and Healthcare Products Regulatory Agency (MHRA) has determined that the balance of risks and benefits favors only the use of fluoxetine in the treatment of depressive illness in children and adolescents. This article reviews the FDA's analysis linking antidepressant medication use and pediatric suicidality in major depressive disorder, discusses the efficacy of antidepressants in treating depression in children and adolescents, and offers suggestions to aid clinicians, patients, and families in making clinical decisions based on an accurate assessment of the benefits and risks of medication and psychosocial treatments for pediatric depression.

引用

页码：404 / 412

页数：9

共 50 条

[1]

[Anonymous], 2000, Evidence- based medicine

[2]

[Anonymous], REL PSYCH DRUGS PED

[3]

Beck, 1979, COGNITIVE THERAPY DE

[4]

Brent D. A., 1996, Psychosocial treatments for child and adolescent disorders: Empirically based strategies for clinical practice, P187, DOI [DOI 10.1037/10196-008, 10.1037/10196-008]

[5] PSYCHIATRIC RISK-FACTORS FOR ADOLESCENT SUICIDE - A CASE-CONTROL STUDY [J].

BRENT, DA ;

PERPER, JA ;

MORITZ, G ;

ALLMAN, C ;

FRIEND, A ;

ROTH, C ;

SCHWEERS, J ;

BALACH, L ;

BAUGHER, M .

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1993, 32 (03) :521-529

[6]

Brent DA, 1997, ARCH GEN PSYCHIAT, V54, P877

[7]

Bridge JA, 2004, JAMA-J AM MED ASSOC, V292, P2578, DOI 10.1001/jama.292.21.2578-b

[8] Review of the efficacy and safety of antidepressants in youth depression [J].

Cheung, AH ;

Emslie, GJ ;

Mayes, TL .

JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 2005, 46 (07) :735-754

[9] Cognitive-behavioral treatment of adolescent depression: Efficacy of acute group treatment and booster sessions [J].

Clarke, GN ;

Rohde, P ;

Lewinsohn, PM ;

Hops, H ;

Seeley, JR .

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1999, 38 (03) :272-279

[10] A DOUBLE-BLIND COMPARISON OF VENLAFAXINE AND FLUOXETINE IN PATIENTS HOSPITALIZED FOR MAJOR DEPRESSION AND MELANCHOLIA [J].

CLERC, GE ;

RUIMY, P ;

VERDEAUPAILLES, J .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1994, 9 (03) :139-143

← 1 2 3 4 5 →